title: Adherence to guidelines for respiratory syncytial virus immunoprophylaxis among infants with prematurity or chronic lung disease in three United States counties.
abstract: Among infants with prematurity and/or chronic lung disease for whom respiratory syncytial virus immunoprophylaxis is recommended, we examined adherence in infants enrolled during healthcare visits for acute respiratory illness in 3 U.S. counties from 2001 to 2007. Immunoprophylaxis among infants who met national criteria for prophylaxis increased from 33% to 83% over the 6-year period; 17% (11/65) of infants who received immunoprophylaxis did not meet eligibility criteria.
authors: Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. kecia.carroll@vanderbilt.edu
authors: Kecia N
authors: KN
authors: Carroll
authors: Marie R
authors: MR
authors: Griffin
authors: Kathryn M
authors: KM
authors: Edwards
authors: Asad
authors: A
authors: Ali
authors: Yuwei
authors: Y
authors: Zhu
authors: Marika K
authors: MK
authors: Iwane
authors: Peter G
authors: PG
authors: Szilagyi
authors: Mary A
authors: MA
authors: Staat
authors: Timothy P
authors: TP
authors: Stevens
authors: Caroline B
authors: CB
authors: Hall
authors: John V
authors: JV
authors: Williams
authors: Tina V
authors: TV
authors: Hartert
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use; D002908:Chronic Disease; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D000069455:Palivizumab; D017410:Practice Guidelines as Topic; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy*; D013997:Time Factors; D014481:United States / Q000453:epidemiology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab